Somatic Structural Rearrangements in Genetically Engineered Mouse Mammary Tumors

Overview

Journal Genome Biol

Specialties Biology
Genetics

Date 2010 Oct 15

PMID 20942901

Citations 16

Authors

Ignacio Varela

Christiaan Klijn

Phillip J Stephens

Laura J Mudie

Lucy Stebbings

Danushka Galappaththige

Hanneke van der Gulden

Eva Schut

Sjoerd Klarenbeek

Peter J Campbell

Lodewyk Fa Wessels

Michael R Stratton

Jos Jonkers

P Andrew Futreal

David J Adams

Affiliations

Soon will be listed here.

Abstract

Background: Here we present the first paired-end sequencing of tumors from genetically engineered mouse models of cancer to determine how faithfully these models recapitulate the landscape of somatic rearrangements found in human tumors. These were models of Trp53-mutated breast cancer, Brca1- and Brca2-associated hereditary breast cancer, and E-cadherin (Cdh1) mutated lobular breast cancer.

Results: We show that although Brca1- and Brca2-deficient mouse mammary tumors have a defect in the homologous recombination pathway, there is no apparent difference in the type or frequency of somatic rearrangements found in these cancers when compared to other mouse mammary cancers, and tumors from all genetic backgrounds showed evidence of microhomology-mediated repair and non-homologous end-joining processes. Importantly, mouse mammary tumors were found to carry fewer structural rearrangements than human mammary cancers and expressed in-frame fusion genes. Like the fusion genes found in human mammary tumors, these were not recurrent. One mouse tumor was found to contain an internal deletion of exons of the Lrp1b gene, which led to a smaller in-frame transcript. We found internal in-frame deletions in the human ortholog of this gene in a significant number (4.2%) of human cancer cell lines.

Conclusions: Paired-end sequencing of mouse mammary tumors revealed that they display significant heterogeneity in their profiles of somatic rearrangement but, importantly, fewer rearrangements than cognate human mammary tumors, probably because these cancers have been induced by strong driver mutations engineered into the mouse genome. Both human and mouse mammary cancers carry expressed fusion genes and conserved homozygous deletions.

Citing Articles

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor.

Turner-Ivey B, Fromm Longo J, Jenkins D, Guest S, Carroll S J Vis Exp. 2023; (198).

PMID: 37677047 PMC: 11188578. DOI: 10.3791/65430.

SEMMs: Somatically Engineered Mouse Models. A New Tool for Disease Modeling for Basic and Translational Research.

Lima A, Maddalo D Front Oncol. 2021; 11:667189.

PMID: 33968774 PMC: 8103029. DOI: 10.3389/fonc.2021.667189.

Genomic variants in mouse model induced by azoxymethane and dextran sodium sulfate improperly mimic human colorectal cancer.

Pan Q, Lou X, Zhang J, Zhu Y, Li F, Shan Q Sci Rep. 2017; 7(1):25.

PMID: 28154415 PMC: 5453956. DOI: 10.1038/s41598-017-00057-3.

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.

McFadden D, Politi K, Bhutkar A, Chen F, Song X, Pirun M Proc Natl Acad Sci U S A. 2016; 113(42):E6409-E6417.

PMID: 27702896 PMC: 5081629. DOI: 10.1073/pnas.1613601113.

The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis.

Jones K, Barrott J, Xie M, Haldar M, Jin H, Zhu J Oncogene. 2016; 35(38):5021-32.

PMID: 26947017 PMC: 5014712. DOI: 10.1038/onc.2016.38.

References

Derksen P, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B . Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006; 10(5):437-49. DOI: 10.1016/j.ccr.2006.09.013. View

Lee W, Jiang Z, Liu J, Haverty P, Guan Y, Stinson J . The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465(7297):473-7. DOI: 10.1038/nature09004. View

Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A . Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 2001; 29(4):418-25. DOI: 10.1038/ng747. View

Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K . Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216):1069-75. PMC: 2694412. DOI: 10.1038/nature07423. View

Bignell G, Greenman C, Davies H, Butler A, Edkins S, Andrews J . Signatures of mutation and selection in the cancer genome. Nature. 2010; 463(7283):893-8. PMC: 3145113. DOI: 10.1038/nature08768. View

Silver D, Richardson A, Eklund A, Wang Z, Szallasi Z, Li Q . Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010; 28(7):1145-53. PMC: 2834466. DOI: 10.1200/JCO.2009.22.4725. View

Rottenberg S, Jaspers J, Kersbergen A, van der Burg E, Nygren A, Zander S . High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008; 105(44):17079-84. PMC: 2579381. DOI: 10.1073/pnas.0806092105. View

Ley T, Mardis E, Ding L, Fulton B, McLellan M, Chen K . DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008; 456(7218):66-72. PMC: 2603574. DOI: 10.1038/nature07485. View

Maser R, Choudhury B, Campbell P, Feng B, Wong K, Protopopov A . Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007; 447(7147):966-71. PMC: 2714968. DOI: 10.1038/nature05886. View

10.

Stephens P, McBride D, Lin M, Varela I, Pleasance E, Simpson J . Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009; 462(7276):1005-10. PMC: 3398135. DOI: 10.1038/nature08645. View

11.

Campbell P, Stephens P, Pleasance E, OMeara S, Li H, Santarius T . Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet. 2008; 40(6):722-9. PMC: 2705838. DOI: 10.1038/ng.128. View

12.

Mattison J, Kool J, Uren A, de Ridder J, Wessels L, Jonkers J . Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res. 2010; 70(3):883-95. PMC: 2880710. DOI: 10.1158/0008-5472.CAN-09-1737. View

13.

Kadota M, Yang H, Gomez B, Sato M, Clifford R, Meerzaman D . Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One. 2010; 5(2):e9201. PMC: 2821407. DOI: 10.1371/journal.pone.0009201. View

14.

Pleasance E, Cheetham R, Stephens P, McBride D, Humphray S, Greenman C . A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009; 463(7278):191-6. PMC: 3145108. DOI: 10.1038/nature08658. View

15.

Rangarajan A, Weinberg R . Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer. 2004; 3(12):952-9. DOI: 10.1038/nrc1235. View

16.

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View

17.

Dupuy A, Akagi K, Largaespada D, Copeland N, Jenkins N . Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005; 436(7048):221-6. DOI: 10.1038/nature03691. View

18.

Nakagawa T, Pimkhaokham A, Suzuki E, Omura K, Inazawa J, Imoto I . Genetic or epigenetic silencing of low density lipoprotein receptor-related protein 1B expression in oral squamous cell carcinoma. Cancer Sci. 2006; 97(10):1070-4. PMC: 11159176. DOI: 10.1111/j.1349-7006.2006.00283.x. View

19.

Ding L, Ellis M, Li S, Larson D, Chen K, Wallis J . Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010; 464(7291):999-1005. PMC: 2872544. DOI: 10.1038/nature08989. View

20.

Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A . Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007; 104(29):12111-6. PMC: 1924557. DOI: 10.1073/pnas.0702969104. View